These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 17464877

  • 1. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab.
    Kalyoncu U, Karadag O, Akdogan A, Kisacik B, Erman M, Erguven S, Ertenli AI.
    Scand J Infect Dis; 2007; 39(5):475-8. PubMed ID: 17464877
    [Abstract] [Full Text] [Related]

  • 2. Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.
    Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M, Komano Y, Akiyama Y, Mimura T, Kaneko M, Tokuda H, Iso T, Motegi M, Ikeda K, Nakajima H, Taki H, Kubota T, Kodama H, Sugii S, Kuroiwa T, Nawata Y, Shiozawa K, Ogata A, Sawada S, Matsukawa Y, Okazaki T, Mukai M, Iwahashi M, Saito K, Tanaka Y, Nanki T, Miyasaka N, Harigai M.
    Mod Rheumatol; 2013 Nov; 23(6):1085-93. PubMed ID: 23212592
    [Abstract] [Full Text] [Related]

  • 3. [Pneumocystis pneumonia developed in two patients with rheumatoid arthritis during treatment of adalimumab].
    Ikeuchi H, Umemoto A, Tsukida M, Sakurai N, Maeshima A, Kuroiwa T, Hiromura K, Nojima Y.
    Nihon Rinsho Meneki Gakkai Kaishi; 2011 Nov; 34(5):420-5. PubMed ID: 22041430
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody.
    Mori S, Imamura F, Kiyofuji C, Ito K, Koga Y, Honda I, Sugimoto M.
    Mod Rheumatol; 2006 Nov; 16(1):58-62. PubMed ID: 16622728
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE, Schaible TF, Boscia JA.
    JAMA; 2006 Nov 08; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pneumocystis carinii pneumonia following a second infusion of infliximab.
    Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M.
    Rheumatology (Oxford); 2002 Aug 08; 41(8):951-2. PubMed ID: 12154220
    [No Abstract] [Full Text] [Related]

  • 16. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.
    J Rheumatol; 2003 Dec 08; 30(12):2563-71. PubMed ID: 14719195
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK, Siegel JN.
    JAMA; 2006 Nov 08; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 08; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.